BIGG

Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer

England. National Institute for Health and Care Excellence.

Année de publication: 2023

Evidence-based recommendations on pembrolizumab (Keytruda) plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer in adults.

Uterine Cervical Neoplasms/secondary, Uterine Cervical Neoplasms/drug therapy, Antibodies, Monoclonal/therapeutic use, Drug Therapy, Combination

Texte intégral